Evidence map›Paper›PMID 29332604›Full record

Trial reportFluids and barriers of the CNS2018

The effect of an adenosine A

Sadhana Jackson, Jon Weingart, Edjah K Nduom, Thura T Harfi, Richard T George, Dorothea McAreavey, Xiaobu Ye, Nicole M Anders, Cody Peer, William D Figg and 3 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Fluids and barriers of the CNS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood-Brain Barrier Opening.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Sadhana JacksonBrain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA. Sadhana.jackson@nih.gov.
Jon WeingartSchool of Medicine, Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, 21287, USA.
Edjah K NduomSurgical Neurology Branch, NINDS/NIH, 10 Center Drive, 3D20, Bethesda, MD, 20814, USA.
Thura T HarfiDavid Heart & Lung Research Institute, The Ohio State University, 374 12th Avenue, Suite 200, Columbus, OH, 43210, USA.
Richard T GeorgeHeart and Vascular Institute, Johns Hopkins University, 600 N. Wolfe Street, Sheikh Zayed Tower, Baltimore, MD, 21287, USA.
Dorothea McAreaveyCritical Care Medicine Department, Nuclear Cardiology Section, NIH Clinical Center, 10 Center Drive, Bethesda, MD, 20892, USA.
Xiaobu YeSchool of Medicine, Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, 21287, USA.
Nicole M AndersCancer Chemical and Structural Biology and Analytical Pharmacology Core Laboratory, Johns Hopkins University, Bunting-Blaustein Cancer Research Building I, 1650 Orleans Street, CRB1 Room 1M52, Baltimore, MD, 21231, USA.
Cody PeerClinical Pharmacology, NCI/NIH, 10 Center Drive, 5A01, Bethesda, MD, 20814, USA.
William D FiggClinical Pharmacology, NCI/NIH, 10 Center Drive, 5A01, Bethesda, MD, 20814, USA.
Mark GilbertNeuro-Oncology Branch, NCI/NIH, 9030 Old Georgetown Rd, Building 82, Bethesda, MD, 20892, USA.
Michelle A RudekCancer Chemical and Structural Biology and Analytical Pharmacology Core Laboratory, Johns Hopkins University, Bunting-Blaustein Cancer Research Building I, 1650 Orleans Street, CRB1 Room 1M52, Baltimore, MD, 21231, USA.
Stuart A GrossmanBrain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA.
Johns Hopkins University · USNational Institutes of Health · USNational Institutes of Health Clinical Center · USThe Ohio State University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Molecular Pathogenesis of NeoplasiaZIANS003052 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI HEISS, JOHN · 2009 to 2025
$20.7M
Sample Processing and Analytical Methods Development for New Anticancer AgentsZICSC006536 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$18.1M
Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$14.4M
Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
National Center for Advancing Translational Sciences UL1 TR 001079National Institutes of Health UL1 TR 001079National Institutes of Health (US) P30CA006973National Institutes of Health (US) T32GM066691NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NIGMS NIH HHS T32 GM066691
6 · The paper itself

Abstract

backgroundThe blood-brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A

methodsPatients scheduled for a clinically indicated surgery for recurrent glioblastoma were eligible. Microdialysis catheters (MDC) were placed intraoperatively, and the positions were documented radiographically. On post-operative day #1, patients received oral temozolomide (150 mg/m

resultsSix patients were enrolled. Five patients had no complications from the MDC placement or regadenoson and had successful collection of blood and dialysate samples. The mean plasma AUC was 16.4 ± 1.4 h µg/ml for temozolomide alone and 16.6 ± 2.87 h µg/ml with addition of regadenoson. The mean dialysate AUC was 2.9 ± 1.2 h µg/ml with temozolomide alone and 3.0 ± 1.7 h µg/ml with regadenoson. The mean brain:plasma AUC ratio was 18.0 ± 7.8 and 19.1 ± 10.7% for temozolomide alone and with regadenoson respectively. Peak concentration and T

conclusionsAlthough previously shown to be efficacious in rodents to increase varied size agents to cross the BBB, our data suggest that regadenoson does not increase temozolomide concentrations in brain. Further studies exploring alternative doses and schedules are needed; as transiently disrupting the BBB to facilitate drug entry is of critical importance in neuro-oncology.

Indexed as

Adenosine A2 Receptor AgonistsAdministration, IntravenousAdministration, OralAdultAgedAntineoplastic Agents, AlkylatingBrainBrain NeoplasmsDacarbazineFeasibility StudiesFemaleGlioblastomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalAdenosine A2 Receptor AgonistsAntineoplastic Agents, AlkylatingDacarbazinePurinesPyrazolesReceptor, Adenosine A2AregadenosonTemozolomideAdenosine A2A agonistBlood–brain barrierGlioblastomaHigh grade gliomaMicrodialysisRegadenosonTemozolomide

Identifiers

PMID29332604
PMCPMC5767971
OpenAlexW2783261636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.